Literature DB >> 6226991

[Malignant form of Mediterranean boutonneuse fever. 6 cases].

D Raoult, H Gallais, A Ottomani, J P Resch, D Tichadou, P De Micco, P Casanova.   

Abstract

Six cases of severe Mediterranean boutonneuse fever are reported. The clinical diagnosis, based on the presence of summer fever with an erythematous rash plus an escharr in three patients, was confirmed by serology (microagglutination in 1 case, indirect immunofluorescence in 4). The symptoms resembled those of Rocky Mountain spotted fever associating, as they did, a purpuric rash with neurological signs (impaired consciousness in all 6 cases, convulsion in 2), respiratory symptoms (5) and digestive signs (diarrhoea in 1 case, enlargement of the liver in 4). Laboratory examinations showed thrombopenia (6), rise in serum transaminases (5), LDH (5) and CPK (6), increased in blood urea and creatinine levels (6), hyponatraemia (6), hypokaliaemia (5) and hypocalcaemia (5). Two patients treated with doxycycline recovered and 4 died. Among these, 1 had received erythromycin, 1 a tetracycline and 1 doxycycline.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6226991

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  14 in total

1.  Clinical and laboratory characteristics of 144 patients with mediterranean spotted fever.

Authors:  E Antón; B Font; T Muñoz; I Sanfeliu; F Segura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-18       Impact factor: 3.267

Review 2.  Host, pathogen and treatment-related prognostic factors in rickettsioses.

Authors:  E Botelho-Nevers; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-26       Impact factor: 3.267

3.  Plasma interleukin-6 levels in Mediterranean spotted fever.

Authors:  J Oristrell; M Sampere; M J Amengual; B Font; F Segura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-22       Impact factor: 3.267

4.  Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever.

Authors:  F Gudiol; R Pallares; J Carratala; F Bolao; J Ariza; G Rufi; P F Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

5.  Malignant boutonneuse fever and polymyalgia rheumatica: a coincidental association?

Authors:  G Chaumentin; T Zénone; C Bibollet; G A Denoyel; A Boibieux; F Biron; D Peyramond
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

6.  Muscular damage in Mediterranean spotted fever.

Authors:  F Bella; E Espejo; M R Bella; B Font; I Ferrer; F Segura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 7.  New trends in Mediterranean spotted fever.

Authors:  F Segura-Porta; B Font-Creus; E Espejo-Arenas; F Bella-Cueto
Journal:  Eur J Epidemiol       Date:  1989-12       Impact factor: 8.082

8.  Analysis of T-cell-dependent and -independent antigens of Rickettsia conorii with monoclonal antibodies.

Authors:  H M Feng; D H Walker; J G Wang
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

9.  Erythromycin versus tetracycline for treatment of Mediterranean spotted fever.

Authors:  T Muñoz-Espin; P López-Parés; E Espejo-Arenas; B Font-Creus; I Martinez-Vila; J Travería-Casanova; F Segura-Porta; F Bella-Cueto
Journal:  Arch Dis Child       Date:  1986-10       Impact factor: 3.791

10.  Ciprofloxacin therapy for Mediterranean spotted fever.

Authors:  D Raoult; H Gallais; P De Micco; P Casanova
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.